natgillin/translations-raw huggingface dataset:
Insulin Human Winthrop Comb 15 100 IU/ ml suspension for injection in a pre-filled pen.
Insulin Human Winthrop Comb 15 100 i. e. / ml suspenzija za injiciranje v napolnjenem injekcijskem peresniku
Insulin Human Winthrop Comb 15 is a biphasic isophane insulin suspension consisting of 15% dissolved insulin and 85% crystalline protamine insulin.
Insulin Human Winthrop Comb 15 je dvofazna suspenzija insulina isofana, sestavljena iz 15% raztopljenega insulina in 85% kristalnega protamin- insulina.
The need to adjust (e. g. reduce) the dose may become evident immediately after transfer.
139 Potreba po prilagoditvi (npr. zmanjšanju) odmerka se lahko pokaže takoj po prehodu.
145 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
Before using OptiSet, the Instructions for Use included in the Package Leaflet must be read carefully.
Pred uporabo OptiSeta natančno preberite navodila za ravnanje z OptiSetom v navodilu za uporabo (glejte 6. 6).
In patients with severe hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.
140 Pri bolnikih s hudo okvaro jeter se lahko potreba po insulinu zmanjša zaradi zmanjšane zmožnosti za glukoneogenezo in zmanjšane presnove insulina.
146 In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
V primeru nezadostne urejenosti glukoze ali nagnjenosti k hiper - ali hipoglikemijam je treba pred spreminjanjem odmerka preveriti, ali bolnik upošteva predpisano shemo zdravljenja, mesta injiciranja, ustreznost načina injiciranja in vse druge pomembne dejavnike.
147 Handling of the pen
141 Ravnanje z injekcijskim peresnikom
OptiSet has to be used as recommended in these Instructions for Use (see section 6.6).
OptiSet uporabljajte kot je priporočeno v navodilih za ravnanje z OptiSetom (glejte poglavje 6. 6).
148 4.8 Undesirable effects
4. 8 Neželeni učinki
149 As with any insulin therapy, lipodystrophy may occur at the injection site and delay local insulin absorption.
143 Tako kot pri zdravljenju z vsakim insulinom se lahko na mestu injiciranja pojavi lipodistrofija, ki upočasni lokalno absorpcijo insulina.
150 5.2 Pharmacokinetic properties
5. 2 Farmakokinetične lastnosti
In healthy subjects, the serum half-life of insulin is approximately 4 to 6 minutes.
144 Pri zdravih osebah je razpolovni čas insulina v serumu približno 4 do 6 minut.
Protamine sulphate, metacresol, phenol, zinc chloride, sodium dihydrogen phosphate dihydrate, glycerol, sodium hydroxide, hydrochloric acid (for pH adjustment), water for injections.
Protaminijev sulfat, metakrezol, fenol, cinkov klorid, natrijev dihidrogenfosfat dihidrat, glicerol, natrijev hidroksid, klorovodikova kislina (za uravnavanje pH). voda za injekcije.
151 6.5 Nature and contents of container
6. 5 Vrsta ovojnine in vsebina
3 ml suspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
145 3 ml suspenzija v vložku (iz brezbarvnega stekla tipa 1), z batom (iz brombutilne gume (tip 1)) ter prirobljeno zaporko (iz aluminija) z zamaškom (iz brombutilne ali laminata poliizoprenske in brombutilne gume (tip 1)).
Before first use, Insulin Human Winthrop Comb 15 must be kept at room temperature for 1 to 2 hours and then resuspended to check the contents.
Pred prvo uporabo mora biti Insulin Human Winthrop Comb 1 do 2 uri na sobni temperaturi; potem ga je treba za preverjanje vsebine ponovno suspendirati.
Insulin Human Winthrop Comb 15 must not be used if this cannot be achieved, i. e. if the suspension remains clear, for example, or if clumps, particles or flocculation appear in the insulin or stick to the wall or bottom of the cartridge.
Insulina Insulin Human Winthrop Comb 15 se ne sme uporabiti, če tega ni mogoče doseči, tj. suspenzija npr. ostane bistra, se v insulinu pojavijo grude, delci ali kosmi ali se lepijo na steno ali dno vložka.
Insulin Human Winthrop Comb 15 must not be mixed with any other insulin or with insulin analogues.
Insulin Human Winthrop Comb 15 se ne sme mešati z nobenim drugim insulinom ali insulinskimi analogi.
152 Handling of the pen The Instructions for Use included in the Package Leaflet must be read carefully before using OptiSet.
146 Ravnanje z injekcijskim peresnikom Pred uporabo OptiSeta natančno preberite navodila za ravnanje z OptiSetom v navodilu za uporabo.
The insulin should be mixed by turning OptiSet slowly up and down at least 10 times.
147 Insulin je treba premešati tako, da OptiSet vsaj 10- krat počasi obrnete navzgor in navzdol.
153 Step 2.
Korak 2.
If a dose greater than 40 units is required, it should be given as two or more injections.
Če je potrebni odmerek večji od 40 enot, ga je treba dati z dvema ali več injiciranji..
The injection button allows checking the actual loaded dose.
148 Gumb za injiciranje omogoča preverjanje dejansko napolnjenega odmerka.
154 Step 6.
Korak 6.
155 1.
149 1.
Suspension for injectionin a cartridge for OptiClik.
Suspenzija za injiciranje v vložku za injekcijski peresnik OptiClik.
156 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
150 Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
Insulin Human Winthrop Comb 15 in cartridges for OptiClik has been developed for use with OptiClik only.
Insulin Human Winthrop Comb 15 v vložkih za injekcijski peresnik OptiClik je pripravljen samo za uporabo v injekcijskih peresnikih OptiClik.
157 In patients with severe hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.
151 Pri bolnikih s hudo okvaro jeter se lahko potreba po insulinu zmanjša zaradi zmanjšane zmožnosti za glukoneogenezo in zmanjšane presnove insulina.
158 Intercurrent illness
Sočasne bolezni
4.5 Interaction with other medicinal products and other forms of interaction
152 4. 5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
159 Patients should be advised to take precautions to avoid hypoglycaemia whilst driving.
Bolnikom je treba svetovati, naj upoštevajo ustrezne varnostne ukrepe, da bi se izognili hipoglikemiji med upravljanjem vozila.
Severe hypoglycaemic attacks, especially if recurrent, may lead to neurological damage.
153 Hude hipoglikemije lahko povzročijo nevrološke okvare, zlasti če se ponavljajo.
160 Skin and subcutaneous tissue disorders
Bolezni kože in podkožja
Common: injection site reactions Uncommon: injection site urticaria Not known: injection site inflammation, injection site swelling, injection site pain, injection site pruritus, injection site erythema.
154 Občasni: urtikarija na mestu injiciranja Ni znano: vnetje na mestu injiciranja, oteklost na mestu injiciranja, bolečina na mestu injiciranja, srbenje na mestu injiciranja, eritem na mestu injiciranja.
161 5.2 Pharmacokinetic properties
5. 2 Farmakokinetične lastnosti
The acute toxicity was studied following subcutaneous administration in rats.
155 Akutno toksičnost so proučili po subkutani uporabi pri podganah.
162 6.5 Nature and contents of container
6. 5 Vrsta ovojnine in vsebina
Packs of 3, 4, 5, 6, 9 or 10 cartridges for OptiClik are available.
156 Na voljo so pakiranja s 3, 4, 5, 6, 9 ali 10 vložki za injekcijski peresnik OptiClik.
163 Insulin Human Winthrop Comb 15 cartridges for OptiClik are not designed to allow any other insulin to be mixed in the cartridge for OptiClik.
Vložki Insulin Human Winthrop Comb 15 za injekcijski peresnik OptiClik niso zasnovani tako, da bi dovoljevali mešanje kakšnega drugega insulina v vložku za injekcijski peresnik OptiClik.
Any unused product or waste material should be disposed of in accordance with local requirements.
157 Neuporabljeno zdravilo ali odpadni material zavrzite v skladu z lokalnimi predpisi.
164 1.
158 1.
Alternatively, it may emerge gradually over a period of several weeks.
159 Po drugi strani pa se lahko pojavi postopoma med obdobjem več tednov.
165 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
166 In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
160 V primeru nezadostne urejenosti glukoze ali nagnjenosti k hiper - ali hipoglikemijam je treba pred spreminjanjem odmerka preveriti, ali bolnik upošteva predpisano shemo zdravljenja, mesta injiciranja, ustreznost načina injiciranja in vse druge pomembne dejavnike.
167 Handling of the pen
161 Ravnanje z injekcijskim peresnikom
168 4.8 Undesirable effects
4. 8 Neželeni učinki
169 As with any insulin therapy, lipodystrophy may occur at the injection site and delay local insulin absorption.
163 Tako kot pri zdravljenju z vsakim insulinom se lahko na mestu injiciranja pojavi lipodistrofija, ki upočasni lokalno absorpcijo insulina.
170 5.2 Pharmacokinetic properties
5. 2 Farmakokinetične lastnosti
In healthy subjects, the serum half-life of insulin is approximately 4 to 6 minutes.
164 Pri zdravih osebah je razpolovni čas insulina v serumu približno 4 do 6 minut.
171 6.5 Nature and contents of container
6. 5 Vrsta ovojnine in vsebina
3 ml suspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
165 3 ml suspenzija v vložku (iz brezbarvnega stekla tipa 1), z batom (iz brombutilne gume (tipa 1)) ter s prirobljeno zaporko (iz aluminija) z zamaškom (iz brombutilne ali laminata poliizoprenske in brombutilne gume (tipa 1)).
172 Handling of the pen
166 Ravnanje z injekcijskim peresnikom
The Instructions for Use included in the Package Leaflet must be read carefully before using SoloStar.
Pred uporabo SoloStarja natančno preberite navodila za ravnanje s SoloStarjem v navodilu za uporabo.
Schematic diagram of the pen
igla peresnika (ni priložena)
173 Step 2.
167 Korak 2.
EU/ 1/ 06/ 368/ XXX EU/ 1/ 06/ 368/ XXX EU/ 1/ 06/ 368/ XXX EU/ 1/ 06/ 368/ XXX EU/ 1/ 06/ 368/ XXX EU/ 1/ 06/ 368/ XXX
168 EU/ 1/ 06/ 368/ XXX EU/ 1/ 06/ 368/ XXX EU/ 1/ 06/ 368/ XXX EU/ 1/ 06/ 368/ XXX EU/ 1/ 06/ 368/ XXX EU/ 1/ 06/ 368/ XXX
175 1.
169 1.
Insulin Human Winthrop Comb 25 100 IU/ ml suspension for injection in a vial
Insulin Human Winthrop Comb 25 100 i. e. / ml suspenzija za injiciranje v viali
Insulin Human Winthrop Comb 25 is a biphasic isophane insulin suspension consisting of 25% dissolved insulin and 75% crystalline protamine insulin.
Insulin Human Winthrop Comb 25 je dvofazna suspenzija insulina izofana, sestavljena iz 25% raztopljenega insulina in 75% kristalnega protamin- insulina.
176 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
170 Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
Insulin Human Winthrop Comb 25 contains 100 IU of insulin per ml suspension.
En mililiter suspenzije Insulin Human Winthrop Comb 25 vsebuje 100 i. e. insulina.
177 In patients with renal impairment, insulin requirements may be diminished due to reduced insulin metabolism.
Pri bolnikih z okvaro ledvic se lahko potreba po insulinu zaradi zmanjšane presnove insulina zmanjša.
In patients with severe hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.
171 Pri bolnikih s hudo okvaro jeter se lahko potreba po insulinu zmanjša zaradi zmanjšane zmožnosti za glukoneogenezo in zmanjšane presnove insulina.
178 Intercurrent illness
Sočasne bolezni
4.5 Interaction with other medicinal products and other forms of interaction
172 4. 5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
Substances that may reduce the blood-glucose-lowering effect include corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, oestrogens and progestogens (e. g. in oral contraceptives), phenothiazine derivatives, somatropin, sympathomimetic agents (e. g. epinephrine [adrenaline], salbutamol, terbutaline), thyroid hormones, protease inhibitors and atypical antipsychotic medicinal products (e. g. olanzapine and clozapine).
Med zdravili oz. snovmi, ki lahko oslabijo hipoglikemično delovanje, so kortikosteroidi, danazol, diazoksid, diuretiki, glukagon, izoniazid, estrogeni in progestageni (npr. v kontracepcijski tabletah), derivati fenotiazina, somatropin, simpatikomimetiki (npr. adrenalin, salbutamol, terbutalin), ščitnični hormoni, zaviralci proteaz in netipična antipsihotična zdravila (npr. olanzapin in klozapin).
No effects on the suckling child are anticipated.
Dojenje Učinki na dojenčke niso pričakovani.
Insulin Human Winthrop Comb 25 can be used during breastfeeding.
Zdravilo Insulin Human Winthrop Comb 25 je med dojenjem dovoljeno uporabljati.
179 4.8 Undesirable effects
4. 8 Neželeni učinki
Severe hypoglycaemic attacks, especially if recurrent, may lead to neurological damage.
173 Hude hipoglikemije lahko povzročijo nevrološke okvare, zlasti če se ponavljajo.
180 As with any insulin therapy, lipodystrophy may occur at the injection site and delay local insulin absorption.
Tako kot pri zdravljenju z vsakim insulinom se lahko na mestu injiciranja pojavi lipodistrofija, ki upočasni lokalno absorpcijo insulina.
Common: injection site reactions Uncommon: injection site urticaria Not known: injection site inflammation, injection site swelling, injection site pain, injection site pruritus, injection site erythema.
174 Ni znano: vnetje na mestu injiciranja, oteklost na mestu injiciranja, bolečina na mestu injiciranja, srbenje na mestu injiciranja, eritem na mestu injiciranja.
Insulin Human Winthrop Comb 25 (a biphasic isophane insulin suspension with 25% dissolved insulin) is an insulin with gradual onset and long duration of action.
Insulin Human Winthrop Comb 25 (dvofazna suspenzija insulina izofana s 25% raztopljenega insulina) je insulin s postopnim začetkom in dolgim trajanjem delovanja.
181 5.2 Pharmacokinetic properties
5. 2 Farmakokinetične lastnosti
The acute toxicity was studied following subcutaneous administration in rats.
175 Akutno toksičnost so proučili po subkutani uporabi pri podganah.
182 6.5 Nature and contents of container
6. 5 Vrsta ovojnine in vsebina
6.6 Special precautions for disposal and other handling
6. 6 Posebni varnostni ukrepi za odstranjevanje in ravnanje z zdravilom.
Before withdrawing insulin from the vial for the first time, remove the plastic protective cap.
176 Pred prvim izvlekom insulina iz viale odstranite plastično zaščitno zaporko.
Insulin Human Winthrop Comb 25 must not be used if this cannot be achieved, i. e. if the suspension remains clear, for example, or if clumps, particles or flocculation appear in the insulin or stick to the wall or bottom of the vial.
Insulina Insulin Human Winthrop Comb 25 se ne sme uporabiti, če tega ni mogoče doseči – če suspenzija npr. ostane bistra, se v insulinu pojavijo grude, delci ali kosmi ali se lepijo na steno ali dno viale.
As with all insulin preparations, Insulin Human Winthrop Comb 25 must not be mixed with solutions containing reducing agents such as thioles and sulphites.
Tako kot velja za vse pripravke insulinov, tudi zdravila Insulin Human Winthrop Comb 25 ne smete mešati z raztopinami, ki vsebujejo reducente, npr. tiole ali sulfite.
Insulin Human Winthrop Comb 25 may be mixed with all Sanofi-Aventis human insulins, but NOT with those designed specifically for use in insulin pumps.
Insulin Human Winthrop Comb 25 se sme mešati z vsemi humanimi insulini, ki jih izdeluje Sanofi - Aventis, NE pa s tistimi, ki so posebej pripravljeni za uporabo v insulinskih črpalkah.
Insulin Human Winthrop Comb 25 must also NOT be mixed with insulins of animal origin or with insulin analogues.
Zdravila Insulin Human Winthrop Comb 25 prav tako NE smete mešati z insulini živalskega izvora ali insulinskimi analogi.
184 1.
177 1.
Insulin Human Winthrop Comb 25 40 IU/ ml suspension for injection in a vial
Insulin Human Winthrop Comb 25 40 i. e. / ml suspenzija za injiciranje v viali
185 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
178 Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
Insulin Human Winthrop Comb 25 contains 40 IU of insulin per ml suspension.
En mililiter suspenzije Insulin Human Winthrop Comb 25 vsebuje 40 i. e. insulina.
186 In patients with renal impairment, insulin requirements may be diminished due to reduced insulin metabolism.
Pri bolnikih z okvaro ledvic se lahko potreba po insulinu zaradi zmanjšane presnove insulina zmanjša.
In patients with severe hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.
179 Pri bolnikih s hudo okvaro jeter se lahko potreba po insulinu zmanjša zaradi zmanjšane zmožnosti za glukoneogenezo in zmanjšane presnove insulina.
187 Intercurrent illness
Sočasne bolezni
4.5 Interaction with other medicinal products and other forms of interaction
180 4. 5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
Pregnancy
4. 6 Nosečnost in dojenje
For insulin human, no clinical data on exposed pregnancies are available.
Nosečnost Za humani insulin ni na voljo kliničnih podatkov od nosečnic, ki so bile izpostavljene zdravilu.
188 4.8 Undesirable effects
4. 8 Neželeni učinki
Severe hypoglycaemic attacks, especially if recurrent, may lead to neurological damage.
181 Hude hipoglikemije lahko povzročijo nevrološke okvare, zlasti če se ponavljajo.
189 As with any insulin therapy, lipodystrophy may occur at the injection site and delay local insulin absorption.
Tako kot pri zdravljenju z vsakim insulinom se lahko na mestu injiciranja pojavi lipodistrofija, ki upočasni lokalno absorpcijo insulina.
Common: injection site reactions Uncommon: injection site urticaria Not known: injection site inflammation, injection site swelling, injection site pain, injection site pruritus, injection site erythema.
182 Ni znano: vnetje na mestu injiciranja, oteklost na mestu injiciranja, bolečina na mestu injiciranja, srbenje na mestu injiciranja, eritem na mestu injiciranja.
190 5.2 Pharmacokinetic properties
5. 2 Farmakokinetične lastnosti
The acute toxicity was studied following subcutaneous administration in rats.
183 Akutno toksičnost so proučili po subkutani uporabi pri podganah.
191 6.5 Nature and contents of container
6. 5 Vrsta ovojnine in vsebina
6.6 Special precautions for disposal and other handling
184 6. 6 Posebni varnostni ukrepi za odstranjevanje in ravnanje z zdravilom
Insulin Human Winthrop Comb 25 100 IU/ ml suspension for injection in a cartridge
Insulin Human Winthrop Comb 25 100 i. e. / ml suspenzija za injiciranje v vložku
Each ml contains 100 IU insulin human (equivalent to 3.5 mg).
En mililiter Insulin Human Winthropvsebuje 100 i. e. humanega insulina.
194 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
186 Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
Insulin Human Winthrop Comb 25 in cartridges has been developed for use in the OptiPen series.
Insulin Human Winthrop Comb 25 v vložkih je pripravljen za uporabo v injekcijskih peresnikih OptiPen.
195 In patients with severe hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.
187 Pri bolnikih s hudo okvaro jeter se lahko potreba po insulinu zmanjša zaradi zmanjšane zmožnosti za glukoneogenezo in zmanjšane presnove insulina.
196 Intercurrent illness
Sočasne bolezni
4.5 Interaction with other medicinal products and other forms of interaction
188 4. 5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
197 Patients should be advised to take precautions to avoid hypoglycaemia whilst driving.
Bolnikom je treba svetovati, naj upoštevajo ustrezne varnostne ukrepe, da bi se izognili hipoglikemiji med upravljanjem vozila.
Severe hypoglycaemic attacks, especially if recurrent, may lead to neurological damage.
189 Hude hipoglikemije lahko povzročijo nevrološke okvare, zlasti če se ponavljajo.
198 Skin and subcutaneous tissue disorders
Bolezni kože in podkožja
Common: injection site reactions Uncommon: injection site urticaria Not known: injection site inflammation, injection site swelling, injection site pain, injection site pruritus, injection site erythema.
190 Ni znano: vnetje na mestu injiciranja, oteklost na mestu injiciranja, bolečina na mestu injiciranja, srbenje na mestu injiciranja, eritem na mestu injiciranja.
199 5.2 Pharmacokinetic properties
5. 2 Farmakokinetične lastnosti
The acute toxicity was studied following subcutaneous administration in rats.
191 Akutno toksičnost so proučili po subkutani uporabi pri podganah.
In-use cartridges:
Zdravila Insulin Human Winthrop Comb 25 ne shranjujte v bližini zamrzovalnega razdelka ali zamrzovalnega vložka.
200 6.5 Nature and contents of container
6. 5 Vrsta ovojnine in vsebina
Packs of 3, 4, 5, 6, 9 or 10 cartridges are available.
192 Na voljo so pakiranja s 3, 4, 5, 6, 9 ali 10 vložki.
Cartridges Before insertion into the pen, Insulin Human Winthrop Comb 25 must be kept at room temperature for 1 to 2 hours and then resuspended to check the contents.
Pred vstavitvijo v injekcijski peresnik mora biti Insulin Human Winthrop Comb 25 1 do 2 uri na sobni temperaturi, potem pa ga je treba za preverjanje vsebine ponovno suspendirati.
Insulin Human Winthrop Comb 25 must not be used if this cannot be achieved, i. e. if the suspension remains clear, for example, or if clumps, particles or flocculation appear in the insulin or stick to the wall or bottom of the cartridge.
Insulina Insulin Human Winthrop Comb 25 se ne sme uporabiti, če tega ni mogoče doseči – če suspenzija npr. ostane bistra, se v insulinu pojavijo grude, delci ali kosmi ali se lepijo na steno ali dno vložka.
201 Any unused product or waste material should be disposed of in accordance with local requirements.
Neuporabljeno zdravilo ali odpadni material zavrzite v skladu z lokalnimi predpisi.
202 1.
194 1.
Insulin Human Winthrop Comb 25 100 IU/ ml suspension for injection in a pre-filled pen.
Insulin Human Winthrop Comb 25 100 i. e. / ml suspenzija za injiciranje v napolnjenem injekcijskem peresniku
Each ml contains 100 IU insulin human (equivalent to 3.5 mg).
En mililiter Insulin Human Winthropvsebuje 100 i. e humanega insulina (kar ustreza 3, 5 mg).
The need to adjust (e. g. reduce) the dose may become evident immediately after transfer.
195 Potreba po prilagoditvi (npr. zmanjšanju) odmerka se lahko pokaže takoj po prehodu.
203 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
In patients with severe hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.
196 Pri bolnikih s hudo okvaro jeter se lahko potreba po insulinu zmanjša zaradi zmanjšane zmožnosti za glukoneogenezo in zmanjšane presnove insulina.